Literature DB >> 6433643

Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs.

R Okeda, T Karakama, S Kimura, S Toizumi, T Mitsushima, Y Yokoyama.   

Abstract

5-Fluorouracil (FU) and its masked compounds tegafur (FT) and carmofur (HCFU) were administered orally to Beagle dogs daily for 6 months, and their chronic neurotoxic effects were examined morphologically. In ten dogs that survived the 6-month treatment large vacuoles produced by splitting of the intraperiod line of myelin were observed in the fornix in the wall of the third ventricle. In severely affected dogs large vacuoles developed in the medial preoptic area, medial portion of the internal capsule, the area around the subthalamic nucleus and the mammillo-thalamic tract. Axons of myelinated fibers affected by vacuolation were generally well maintained, and destruction of myelin was not detected. Though proliferation of glia cells or abnormality of oligodendroglia was not detected, a lipid deposit covered by a single layer membrane was observed in the cell bodies and processes of astrocytes. No abnormality was detected by electron microscopy in the cerebrum, inferior colliculus, cerebellum, or pons. Of eight dogs that died during the treatment period, large vacuoles were observed in the fornix in the wall of the third ventricle of four dogs treated for more than 1 month, and large vacuoles were present in the inferior colliculus in two dogs of the FT group in the above four dogs. In the HCFU group, the interruption of treatment for 6 months resulted in alleviation or disappearance of the vacuolar lesions. The above findings suggest that the neurotoxicity of FU and its masked compounds FT and HCFU in long-term treatment produces changes morphologically identical with one another in respect to the site of their manifestation and nature of lesion, that their common degraded product alpha-fluoro-beta-alanine (FBAL) plays a crucial role in their neurotoxic actions, and that vacuolar lesions, to which myelin was more vulnerable than neurons, can develop where the toxic substance readily deposits and accumulates.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433643     DOI: 10.1007/bf00687342

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  28 in total

1.  ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.

Authors:  J L RIEHL; W J BROWN
Journal:  Neurology       Date:  1964-10       Impact factor: 9.910

2.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

Review 3.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

4.  Hexachlorophene neuropathy in rats.

Authors:  J Towfighi; N K Gonatas; L McCree
Journal:  Lab Invest       Date:  1973-10       Impact factor: 5.662

5.  The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.

Authors:  M Chadwick; W I Rogers
Journal:  Cancer Res       Date:  1972-05       Impact factor: 12.701

6.  [The study on metabolic fate of 5-fluorouracil-6-14C after percutaneous administration].

Authors:  T Oishi; H Shiraki; K Mineura; H Takahira
Journal:  Yakugaku Zasshi       Date:  1973-06       Impact factor: 0.302

7.  The distribution of peroxidase in the triethyltin-intoxicated rat brain.

Authors:  A Hirano; H M Dembitzer; N H Becker; H M Zimmerman
Journal:  J Neuropathol Exp Neurol       Date:  1969-07       Impact factor: 3.685

8.  Cerebellar ataxia with weekly 5-fluorouracil administration.

Authors:  J A Gottlieb; J K Luce
Journal:  Lancet       Date:  1971-01-16       Impact factor: 79.321

9.  Cycloleucine encephalopathy.

Authors:  C M Greco; H C Powell; R S Garrett; P W Lampert
Journal:  Neuropathol Appl Neurobiol       Date:  1980 Sep-Oct       Impact factor: 8.090

10.  Metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumour agent, in rats, rabbits and dogs.

Authors:  T Kobari; Y Iguro; A Ujiie; H Namekawa
Journal:  Xenobiotica       Date:  1981-01       Impact factor: 1.908

View more
  7 in total

1.  Carmofur-induced leukoencephalopathy: MRI.

Authors:  S Matsumoto; S Nishizawa; M Murakami; S Noma; A Sano; Y Kuroda
Journal:  Neuroradiology       Date:  1995-11       Impact factor: 2.804

2.  Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.

Authors:  R Okeda; M Shibutani; T Matsuo; T Kuroiwa; R Shimokawa; T Tajima
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 3.  Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative.

Authors:  S Kuzuhara; N Ohkoshi; K Kanemaru; H Hashimoto; T Nakanishi; Y Toyokura
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

4.  Effects of selected repeated intravitreal chemotherapeutic agents.

Authors:  J Vernot; G A Peyman; R Gailitis; R Fiscella; M Woodhouse; D Weinberg
Journal:  Int Ophthalmol       Date:  1985-11       Impact factor: 2.031

Review 5.  Diffusion-weighted MRI in neuro-oncology.

Authors:  Joachim M Baehring; Robert K Fulbright
Journal:  CNS Oncol       Date:  2012-11

6.  A case of neurotoxicity following 5-fluorouracil-based chemotherapy.

Authors:  Seung Seog Ki; Jin Mo Jeong; Seong Ho Kim; Sook Hyang Jeong; Jin Hyuk Lee; Chul Ju Han; You Cheol Kim; Jhin Oh Lee; Young Joon Hong
Journal:  Korean J Intern Med       Date:  2002-03       Impact factor: 2.884

7.  5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.

Authors:  M Arellano; M Malet-Martino; R Martino; T Spector
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.